CCIWA Call (888) 217-1376 24/7 confidential

Vivitrol vs Oral Naltrexone

Vivitrol and oral naltrexone contain the same drug. Naltrexone hydrochloride. The difference is not pharmacology, it is delivery. A daily pill versus a monthly intramuscular injection. That single delivery difference is the entire reason Vivitrol exists as a separate product, and it matters more than people expect.

Vivitrol and oral naltrexone share an active ingredient. Adherence is the entire difference.
AttributeOral naltrexone (ReVia, Depade, generic)Vivitrol (extended-release naltrexone)
Active ingredient Naltrexone HClNaltrexone (microspheres)
Form 50mg tablet daily380mg intramuscular injection monthly
FDA approval Alcohol use disorder (1994), opioid use disorderAlcohol use disorder + opioid use disorder
Adherence reality Most patients stop within 30 to 90 days28 days of guaranteed coverage per shot
Cost without insurance ~$30 to $80 per month generic~$1,500 per shot
Cost with Medicaid Typically $0 to $5 copayTypically $0 copay (J2315)
Liver function monitoring Required - LFTs at baseline and periodicallySame
Pre-treatment requirement 7 to 10 days opioid-free7 to 10 days opioid-free
Naloxone challenge before first dose Recommended for OUD useRecommended
Drug interactions Avoid with opioid pain medsSame
Discontinuation Effect gone in 24 to 72 hoursEffect tapers over 28 days, gone by 35 to 45 days

Why oral naltrexone fails as much as it does

Oral naltrexone has been FDA-approved for alcohol use disorder since 1994 and for opioid use disorder since 1984. It does not work as widely as it should because most patients stop taking it. The COMBINE study (the largest US trial of pharmacotherapy for AUD) found 30 to 40 percent of patients on oral naltrexone discontinued before the trial endpoint. In real-world settings, where motivation fluctuates and prescriptions get forgotten, the dropout rate is worse.

For opioid use disorder, oral naltrexone is even harder. Patients who relapse simply skip a dose and use opioids 24 hours later. The medication does not punish missed doses the way Vivitrol does. There is no built-in protection against the day a patient decides to stop taking it.

Why Vivitrol works around the adherence problem

Vivitrol locks the patient into 28 days of receptor blockade per injection. Once the shot is in, missing a "dose" is not possible until the next appointment. A patient who decides at week three to relapse cannot do it. The naltrexone is still in their system. Trying to use opioids does nothing.

This sounds like a small advantage on paper. In practice it is the largest single advantage Vivitrol has over its oral form. Treatment adherence drives outcomes more than any other variable in MAT.

Where oral naltrexone still makes sense

Cost trade-off

Generic oral naltrexone runs $30 to $80 per month at cash price. Vivitrol's sticker is $1,500 per shot. With insurance, the cash difference often disappears entirely because Medicaid and most commercial plans cover both at $0 to $5 patient cost. Without insurance, oral naltrexone is the only realistic option for most patients without manufacturer copay assistance.

The naloxone challenge test

Both medications carry the same precipitated withdrawal risk if started too soon after opioid use. Most prescribers do a naloxone challenge before the first dose of either form. The patient gets a small dose of naloxone (an opioid blocker that wears off quickly) and is observed for withdrawal symptoms. If nothing happens within 30 to 60 minutes, the patient is opioid-free enough to start naltrexone safely.

The honest take

Vivitrol exists because oral naltrexone has an adherence problem. The drug works. Patients stopping it does not. If a patient can reliably take a daily pill and has strong external motivation (family, employment, legal, sobriety contract), oral naltrexone is fine and much cheaper. For everyone else, Vivitrol is the version of the same medication that actually gets results.

Find providers